retatrutide phase 2 trial new england journal of medicine Number 1 Top Cardiometabolic Story 2023: with #retatrutide, a GIP-GLP-1-GCG receptor triple agonist, resulted in a mean weight reduction of 24.2% after 48 weeks. https://t.co/aED6xEFDI3 Retatrutide UK: New Triple-Agonist Weight
Description
At BASS Bariatric Surgery Center , our surgeons specialize in safe, effective procedures that help patients achieve real, lasting weight lossand freedom from dependence on costly drugs
Female participants and people with obesity ate more food at a snack buffet after drinking the sucralose drink compared to a regular sugar drink
[DOI] [PMC free article] [PubMed] [Google Scholar] 88.Hagar RE, Ehrlich BE
In clinical trials, Tesamorelin did not significantly worsen overall glucose tolerance
So high blood sugar levels, uh, weight loss resistance
Real-world experience adds context that trials cannot capture
